Adults 18 to 99, any sex, with Cervical Cancer or Anal Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
AttitudesPrimary· baseline posttest (test was approximately 5 minutes to complete)
Attitudes toward HPV vaccination for children Scale range: 1-7 (higher score indicates more positive attitude) Subscales were averaged.
Group
Value
95% CI
Gain-framed Messages
5.61
± 1.74
Loss-framed Messages
5.56
± 1.94
Control Messages
5.51
± 1.87
Intention to Vaccinate Free of CostPrimary· baseline posttest (test was approximately 5 minutes to complete)
Intention to have children vaccinated against HPV free of cost Scale range: 1-6 (higher score indicates stronger intention) Subscales were averaged.
Group
Value
95% CI
Gain-framed Messages
4.56
± 1.57
Loss-framed Messages
4.59
± 1.64
Control Messages
4.46
± 1.70
Intention to Vaccinate With CostSecondary· baseline posttest (test was approximately 5 minutes to complete)
Intention to have children vaccinated against HPV free with cost Scale range: 1-6 (higher score indicates stronger intention) Subscales were averaged.
Group
Value
95% CI
Gain-framed Messages
4.17
± 1.70
Loss-framed Messages
4.27
± 1.79
Control Messages
4.08
± 1.82
Sponsor's own description
The goal of this study is to determine the effects of message framing (gain vs. loss) on African American parents' acceptance of the HPV vaccine and how such effects are moderated by parents' salient beliefs prior to message exposure. Participants are randomized into gain and loss conditions in which they view either gain-framed or loss-framed HPV vaccination messages. Key outcome variables include parents' attitudes and intentions toward vaccinating their children against HPV.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
· Phase 2
· recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
· Phase 1
· recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)
· NA
· recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
· NA
· recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
· Phase 2
· recruiting
Other University of Maryland, College Park trials
Trials by the same sponsor.
NCT07134543 — Using the Smart Underwear Device to Determine a Baseline of Flatus Activity Normalized to Fiber Intake
· recruiting
NCT07162376 — How Clinical and Personal Information Shape Physicians' Risk Judgments
· NA
· completed
NCT06985641 — Khanya Ekhaya: A Home-Based Intervention
· NA
· not yet recruiting
NCT06724705 — Testing the Capability of the Smart Underwear Device to Detect Increased Microbiome Activity Following Lactose Consumpti
· NA
· recruiting
NCT06305039 — Optimizing Bilateral and Single-sided-deafness Cochlear Implants for Functioning in Complex Auditory Environments
· NA
· enrolling by invitation
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, College Park
Last refreshed: 15 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03856437.